Treatment with the BCL2 inhibitor venetoclax in combination with a hypomethylating agent (azacitidine or decitabine) in elderly and unfit acute myeloid leukemia (AML) patients leads to high remission rates and significantly extends overall survival over the previously available treatment regimens [1, 2]. This evidence concerns the gene BCL2 and acute myeloid leukemia.